Botulinum Toxin: Advancing Treatments for Spasticity

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 1708

Special Issue Editors


E-Mail Website
Guest Editor
Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center – Houston, Houston, TX 77030, USA
Interests: spasticity; motor recovery; neuromodulation; neuropathic pain; neurorehabilitation
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Faculty of Biomedical and Rehabilitation Engineering, University of Health and Rehabilitation Sciences, Qingdao 266071, China
Interests: biomedical signal processing; motor unit; EMG; neuromuscular electrophysiology; neurorehabilitation; myoelectric control
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Physical Medicine & Rehabilitation, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
Interests: botulinum toxin, spasticity management, ultrasound assessment, neurorehabilitation

Special Issue Information

Dear Colleagues,

Botulinum toxin (BoNT) has become the main treatment for spasticity of cerebral and spinal origins, such as stroke, brain injury, spinal cord injury, cerebral palsy, and multiple sclerosis. Although its efficacy in spasticity reduction has been established, especially in limb spasticity, BoNT treatment should be customized for individual patients to achieve the best possible clinical outcome.

For this Special Issue of Toxins, we welcome submissions of original research, case series, perspectives, and comprehensive reviews related to factors that can influence clinical decision making and clinical outcomes in BoNT treatment, including, but not limited to, the following:

  • How to set realistic and achievable goals in BoNT treatment;
  • How to optimize treatment plans if goals are not achieved;
  • Appropriate and additional target muscle selection in upper and lower limb focal spasticity treatment, as the clinical manifestations of spasticity are heterogenous, and the selection of target muscles should consider joint abnormality and the resultant kinetic malalignment, especially in the lower limb;
  • Exploring the adjunct therapies that can best optimize BoNT treatment effects, such as electrical stimulation, extracorporeal shock waves, or exoskeleton treatment;
  • Whether early BoNT treatment can facilitate neuroplasticity and facilitate functional recovery;
  • The effects of BoNT treatment on spastic muscles;
  • The importance of the use of ultrasound to help enhance the delivery of BoNT into spastic muscles, given that these muscles show some changes;
  • The monitoring of spastic muscles over time and after the chronic use of BoNT-A treatment;
  • How to assess and differentiate these effects via electromyographic and sonographic assessment;
  • Whether artificial intelligent models can predict BoNT treatment outcomes and guide and improve BoNT treatment.  

Prof. Dr. Sheng Li
Prof. Dr. Ping Zhou
Prof. Dr. Rajiv Reebye
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • botulinum toxin
  • spasticity
  • spastic muscles
  • electromyography (EMG)
  • ultrasound
  • neurorehabilitation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 438 KB  
Article
Early Botulinum Toxin Type A Injection May Improve Motor Recovery in Patients with Post-Stroke Spasticity: A Secondary Analysis from a Longitudinal Cohort Study
by Alessandro Picelli, Andrea Santamato, Michela Cosma, Alessio Baricich, Carmelo Chisari, Marzia Millevolte, Cristina Del Prete, Ilenia Mazzù, Rita Di Censo, Nicola Smania and Mirko Filippetti
Toxins 2025, 17(11), 558; https://doi.org/10.3390/toxins17110558 - 13 Nov 2025
Viewed by 1100
Abstract
Spasticity after stroke impairs motor control, delays recovery, and reduces quality of life. Botulinum toxin type A is the first-line treatment, but it is often administered in the chronic phase, potentially limiting its impact on rehabilitation. Emerging evidence suggests that earlier treatment may [...] Read more.
Spasticity after stroke impairs motor control, delays recovery, and reduces quality of life. Botulinum toxin type A is the first-line treatment, but it is often administered in the chronic phase, potentially limiting its impact on rehabilitation. Emerging evidence suggests that earlier treatment may enhance recovery, though functional benefits remain uncertain. We conducted a secondary analysis of a multicenter, open-label, longitudinal cohort study to investigate whether the timing of the first botulinum toxin type A injection influences outcomes in post-stroke patients naïve to this treatment. All participants received botulinum toxin injections combined with conventional rehabilitation. Assessments were performed at baseline and at 4, 12, and 24 weeks post-injection. The primary outcome was muscle tone; secondary outcomes included motor strength, sensorimotor recovery, and global disability. Statistical analyses used mixed-effects models and trend tests. Patients treated within 90 days of stroke onset showed greater reductions in spasticity at 4 and 12 weeks compared with later treatment. Despite having more severe baseline impairments, early treated patients demonstrated faster and more pronounced improvements in upper-limb strength, sensorimotor recovery, and global disability. Early toxin administration is associated with enhanced reduction in spasticity and improved motor recovery, particularly in patients with severe initial deficits. Full article
(This article belongs to the Special Issue Botulinum Toxin: Advancing Treatments for Spasticity)
Show Figures

Figure 1

Back to TopTop